Venous Thromboembolism (VTE): Risk, Prevention and Management

Dear Colleagues,

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a major global health concern. It is a leading cause of morbidity and mortality, particularly in hospitalized patients, individuals with cancer, and those with genetic predispositions. Despite significant advances, VTE diagnosis and management continue to pose challenges, requiring ongoing research and innovation.

Current strategies for VTE prevention include pharmacological approaches, such as anticoagulation therapy, and mechanical methods, such as compression devices. However, balancing the effectiveness of anticoagulants with the risk of bleeding complications remains a key concern. New anticoagulant therapies and risk stratification models are being developed to improve patient outcomes. Advances in biomarkers and imaging techniques are also enhancing early detection and treatment precision.

Recent years have seen the emergence of novel reperfusion and supportive strategies for severe cases, including catheter-directed techniques and surgical interventions. Multidisciplinary approaches are becoming increasingly important in optimizing patient care. Additionally, high-risk populations, such as gender-specific groups, cancer patients, and individuals with prolonged immobility, require tailored prevention and treatment strategies. Integrating artificial intelligence (AI) into VTE diagnosis and management is also being explored to enhance predictive modeling and clinical decision-making.

By bringing together expert perspectives, this Special Issue will enhance understanding and optimize VTE management. It serves as a valuable resource for clinicians, researchers, and healthcare professionals striving to reduce VTE-related complications and improve patient outcomes through evidence-based strategies and innovative approaches.

This Special Issue will compile and contextualize recent progress in the field of venous thromboembolism. It will highlight new findings in the pathophysiology, diagnosis, and treatment of VTE, bringing together original research, comprehensive reviews, and case studies to provide a robust reference for ongoing clinical and research endeavors.

Dr. Jorge Moisés
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• pulmonary embolism
• cardiogenic shock
• right ventricle failure
• biomarkers
• risk stratification
• PE treatment
• reperfusion
• artificial intelligence
• bleeding